Experimental study demonstrates that ethyl pyruvate suppresses tissue damage and inflammatory cytokines in acute colitis, suggesting therapeutic and protective potential for bowel disease.
Abstract The effects of Ethyl Pyruvate (EP) before and after colitis in trinitrobenzene sulfonic acid (TNBS) induced colitis were investigated. Animals were divided to Control, EP, Colitis, Pre-colitis, Post-colitis groups. The matrix metalloproteinase 2 (MMP-2), MMP-9, tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), IL-10, IL-1, Nuclear Factor kappa B (NFƘβ), inducible nitric oxide synthase (iNOS), total antioxidant capacity (TAC) in tissue were determined. MMP-9, MMP-2, TNF-α, IL-1, IL-12, IL-17, iNOS, NFκB, high mobility group box 1 protein (HMGB1), and Interferon gamma (IFN-γ) gene expression levels were analyzed. EP treatment decreased macroscopic and microscopic damage scores (p < 0.01) EP treatment decreased most of the inflammatory-related gene expression levels in the pre- and post-colitis compared to the colitis. EP application reduced IL-1 and IL-17, MMP-9, MMP-2, and NFƘβ, especially in the post-colitis group (p < 0.05). The study shown that EP application has a therapeutic effect as well as a protective effect on large intestine in colitis.
No takes yet. Share an insight, caveat, or question.
Yorulmaz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: